<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135745</url>
  </required_header>
  <id_info>
    <org_study_id>OCD PMCF Study 1.02.7003</org_study_id>
    <nct_id>NCT01135745</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)</brief_title>
  <official_title>Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to monitor the safety and performance of Reclaim® Deep Brain
      Stimulation (DBS) Therapy in patients with chronic, severe, treatment-resistant Obsessive
      Compulsive Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OCD is an anxiety disorder characterized by intrusive thoughts or images (obsessions), which
      increase anxiety, commonly accompanied by repetitive or ritualistic actions (compulsions),
      which decrease anxiety. The most frequent symptoms are contamination concerns with consequent
      washing or concerns about harm to self or others with consequent checking.

      Although many OCD patients benefit from pharmacotherapy or CBT, between 7% and 10% of OCD
      patients fail to benefit from these standard treatments and may be considered
      treatment-resistant with a chronic deteriorating course. The most severely afflicted and
      disabled of these patients may be indicated for neurosurgical treatments, often considered as
      a therapy of last resort.

      Neurosurgical procedures currently used in the treatment of severe, treatment-resistant OCD
      include anterior cingulotomy, subcaudate tractotomy, limbic leucotomy (which is a combination
      of the first two procedures) and anterior capsulotomy. The commonality between the different
      neurosurgical procedures is the irreversible lesioning of bilateral neuroanatomical
      structures and/or interconnecting pathways that are believed to be involved in the control of
      affect and limbic function.

      An alternative neurosurgical treatment option to the standard lesioning procedures is
      Reclaim® Deep Brain Stimulation (DBS) Therapy for OCD, which received CE mark in July 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of Adverse Events related to implant procedures, device or stimulation</measure>
    <time_frame>12 months</time_frame>
    <description>Prior to any other study procedures Adverse Events will be assessed at every study visit, i.e. after assessment at the baseline visit this will be implant visit, first parameter selection visit and regular visits after 3, 6, and 12 months treatment. AEs will also be collected at all unscheduled visits prior to all other assessments. AEs and stimulation effects will be categorized and recorded in the patient CRF. An independent clinical event committee will review and adjudicate AEs on a regular basis throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize improvement from baseline in OCD symptoms assessed by YBOCS.</measure>
    <time_frame>12 months</time_frame>
    <description>YBOCS score is taken at baseline and then at post-implant visits after 3, 6 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Deep Brain Stimulation Therapy for OCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reclaim® Deep Brain Stimulation</intervention_name>
    <description>Implant of leads in pre-defined brain area; implant of neurostimulators</description>
    <arm_group_label>Deep Brain Stimulation Therapy for OCD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signing and dating of Informed Consent

          -  male and female patients at least 18 years of age

          -  diagnosis of Obsessive Compulsive Disorder

          -  meeting the definition of treatment resistance

        Exclusion Criteria:

          -  Axis-I disorder primary to OCD

          -  contraindication to implantation

          -  suicide risk

          -  risk of non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loes Gabriels, MD PhD MsEng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Psychiatry at UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Wahl-Kordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Lübeck</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludger Tebartz van Elst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Menchon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bellvitge Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Higueras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Granada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Orsola Gambini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital San Paolo Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Schüpbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Siegried Kasper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry and Psychotherapy Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Radu-Djurfeldt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renana Eitan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah-Hebrew University and Medical Center, Jerusalem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Paolo Polo Universitario</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ciutat Sanitaria I Universitaria de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospita</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <reference>
    <citation>Rauch SL, Dougherty DD, Malone D, Rezai A, Friehs G, Fischman AJ, Alpert NM, Haber SN, Stypulkowski PH, Rise MT, Rasmussen SA, Greenberg BD. A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder. J Neurosurg. 2006 Apr;104(4):558-65.</citation>
    <PMID>16619660</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

